Market data not licensed for redistribution.

Daewoong Pharma

069620 · KOSPI · Pharmaceuticals Manufacturing

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %15.0

Debt ratio % (liabilities / equity)113

Revenue TTM (KRW bn)1,635.2

Op. profit TTM (KRW bn)190.5

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

No scheduled risk events found (last checked 2026-10-30 19:40 KST).

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	1,153.0	1,280.1	1,375.3	1,422.7	1,570.9
Operating profit	88.9	95.8	122.6	147.9	196.8
Net income	30.3	39.2	120.0	23.3	192.9

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	356.5	405.4	411.8	397.1	377.8	448.5
Operating profit	38.7	57.9	56.9	43.3	22.2	68.1
Net income	19.8	40.1	47.3	85.7	25.5	19.9

Largest shareholder

As of the 2025 annual report: (주)대웅 and related parties hold 61.34% of common shares.

Recent disclosures

Date	Filing
2026-09-09	Shareholder meeting 임시주주총회결과	DART original
2026-09-09	Governance / misc. (routine) 독립이사의선임ㆍ해임또는중도퇴임에관한신고	DART original
2026-09-04	Debt guarantee / collateral for others 타인에대한채무보증결정	DART original
2026-09-02	Litigation 소송등의제기ㆍ신청(일정금액이상의청구)	DART original
2026-08-25	Shareholder meeting 의결권대리행사권유참고서류	DART original
2026-08-25	Shareholder meeting 주주총회소집공고	DART original
2026-08-21	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-08-14	Periodic report (annual/half/quarterly) 반기보고서 (2026.06)	DART original
2026-07-29	Preliminary earnings 영업(잠정)실적(공정공시)	DART original
2026-07-28	Shareholder meeting 주주총회소집결의	DART original
2026-07-28	Shareholder meeting 주주명부폐쇄기간또는기준일설정	DART original
2026-07-10	Clinical trial / regulatory approval 투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법))	DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-09-02	Litigation	-5.6%	-2.3%	-13.6%
2026-07-29	Preliminary earnings	+3.8%	-0.5%	-14.8%
2026-07-10	Clinical trial / regulatory approval	+1.6%	+7.9%	+12.4%
2026-06-26	Single sales/supply contract	+2.0%	+11.2%	+39.3%
2026-06-23	Clinical trial / regulatory approval	+8.1%	-1.2%	+23.9%
2026-05-26	Clinical trial / regulatory approval	-3.6%	-2.3%	-20.3%
2026-05-21	Other material event (investment-relevant)	-0.8%	+1.2%	-31.1%
2026-05-12	Preliminary earnings	+2.5%	-9.2%	-20.3%
2026-05-12	Other material event (investment-relevant)	+2.5%	-9.2%	-20.3%
2026-05-07	Technology licensing / alliance	+2.9%	-2.8%	-20.1%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view